Latest Clinical Trials
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 2, 2026)
PHASE2 Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE2 FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction Ohio State University Comprehensive Cancer Center NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Roswell Park Cancer Institute NA
COMPLETED
(Sep 1, 2026)
PHASE2 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations Children's Oncology Group NA
RECRUITING
(Sep 1, 2026)
PHASE3 Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL Eastern Cooperative Oncology Group NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Syndax Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE1 Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Children's Oncology Group NA
RECRUITING
(Sep 1, 2026)
PHASE3 A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients M.D. Anderson Cancer Center NA
WITHDRAWN
(Sep 1, 2026)
PHASE1 Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Aug 24, 2026)
PHASE1 Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma Alliance for Clinical Trials in Oncology NA
COMPLETED
(Aug 1, 2026)
PHASE2 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients Wake Forest University Health Sciences NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation Astellas Pharma Inc NA
COMPLETED
(Aug 1, 2026)
PHASE3 Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Technische Universität Dresden NA
COMPLETED
(Aug 1, 2026)
PHASE1, PHASE2 A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE2 Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Diagnosed AML West Virginia University NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 Niclosamide in Pediatric Patients With Relapsed and Refractory AML Stanford University NA
RECRUITING
(Aug 1, 2026)
PHASE1 Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. Fondazione Italiana Linfomi - ETS NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 Vyxeos for Induction of Low- or Intermediate-risk. Shaare Zedek Medical Center NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE1 VA vs DA for Newly Diagnosed Hig-risk AML The First Affiliated Hospital of Soochow University NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Kura Oncology, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1 Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML Stelexis BioSciences NA
RECRUITING
(Aug 1, 2026)
PHASE1 L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML Moleculin Biotech, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE2, PHASE3 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE2 Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Uma Borate NA
RECRUITING
(Aug 1, 2026)
PHASE2 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation Syndax Pharmaceuticals NA
RECRUITING
(Aug 1, 2026)
PHASE3 Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) Stichting Hemato-Oncologie voor Volwassenen Nederland NA
RECRUITING
(Aug 1, 2026)
PHASE3 Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia Christer C Nilsson NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL Ruijin Hospital NA
NOT YET RECRUITING
(Aug 1, 2026)
PHASE2 Ponatinib for FLT3-ITD Acute Myelogenous Leukemia Versailles Hospital NA
COMPLETED
(Jul 1, 2026)
PHASE1, PHASE2 Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Wake Forest University Health Sciences NA
COMPLETED
(Jul 1, 2026)
PHASE1 A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML Novartis Pharmaceuticals NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE2 Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center NA
COMPLETED
(Jul 1, 2026)
PHASE2 Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia PrECOG, LLC. NA
COMPLETED
(Jul 1, 2026)
PHASE2 Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia OHSU Knight Cancer Institute NA
RECRUITING
(Jul 1, 2026)
PHASE1 Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms Fred Hutchinson Cancer Center NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea Hyoung Jin Kang NA
RECRUITING
(Jul 1, 2026)
PHASE2 MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma Masonic Cancer Center, University of Minnesota NA
RECRUITING
(Jul 1, 2026)
PHASE2 Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Fred Hutchinson Cancer Center NA
RECRUITING
(Jul 1, 2026)
PHASE2 Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia OHSU Knight Cancer Institute NA
RECRUITING
(Jul 1, 2026)
PHASE2 Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." Therapeutic Advances in Childhood Leukemia Consortium NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) The First Affiliated Hospital with Nanjing Medical University NA
RECRUITING
(Jul 1, 2026)
PHASE2 Response-adapted Luvometinib With or Without Cytarabine in Langerhans Cell Histiocytosis Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE2 Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML Dana-Farber Cancer Institute NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE1 BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS Case Comprehensive Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia Sanofi NA
TERMINATED
(Jun 1, 2026)
PHASE1 Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) Nantes University Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE1 Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML Daiichi Sankyo NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE3 Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia National Cancer Institute (NCI) NA
COMPLETED
(May 1, 2026)
PHASE3 Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma Christine Ryan NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia M.D. Anderson Cancer Center NA
COMPLETED
(May 1, 2026)
PHASE2 Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University NA
COMPLETED
(May 1, 2026)
PHASE2 Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation Institut de Recherches Internationales Servier NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia University of Southern California NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE2 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia M.D. Anderson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE1 Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia Uma Borate NA
COMPLETED
(May 1, 2026)
PHASE1 Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia Northwestern University NA
TERMINATED
(May 1, 2026)
PHASE1 Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia M.D. Anderson Cancer Center NA
COMPLETED
(May 1, 2026)
PHASE1 Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1 Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma Institute of Hematology & Blood Diseases Hospital, China NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Fred Hutchinson Cancer Center NA
RECRUITING
(May 1, 2026)
PHASE1, PHASE2 A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL Tongji Hospital NA
RECRUITING
(May 1, 2026)
PHASE2 Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms Ohio State University Comprehensive Cancer Center NA
TERMINATED
(Apr 1, 2026)
PHASE1, PHASE2 Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT University of Birmingham NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2, PHASE3 Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia St. Jude Children's Research Hospital NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1 A Study Comparing Rituximab/Bendamustin(RB) Alternating With Rituximab/Bendamustin/Cytarabin(RBAC) With RB Therapy in Elderly Patients With Mentle Cell Lymphoma Kim, Seok Jin NA
RECRUITING
(Apr 1, 2026)
PHASE2 A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Children's Oncology Group NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy Children's Oncology Group NA
RECRUITING
(Apr 1, 2026)
PHASE1 A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Children's Oncology Group NA
WITHDRAWN
(Apr 1, 2026)
PHASE1 VEN+IDAC vs IDAC in AML Guangdong Second Provincial General Hospital NA
ENROLLING BY INVITATION
(Apr 1, 2026)
PHASE2, PHASE3 Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy Fujian Medical University Union Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE1 Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia Shenzhen University General Hospital NA
RECRUITING
(Apr 1, 2026)
PHASE2 Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 University of Ulm NA
RECRUITING
(Mar 1, 2026)
PHASE3 Phase IB/II of CPX-351 for Relapse Prevention in AML Georgetown University NA
RECRUITING
(Mar 1, 2026)
PHASE1, PHASE2 CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics Centre Hospitalier Universitaire de Nice NA
RECRUITING
(Mar 1, 2026)
PHASE2 Revumenib in Combination With 7+3 + Midostaurin in AML Richard Stone, MD NA
RECRUITING
(Mar 1, 2026)
PHASE1 Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients PETHEMA Foundation NA
RECRUITING
(Mar 1, 2026)
PHASE2 
